With one FDA-registered factory and two R&D centers, Sintaho leverages platforms in high-potency small molecules, XDC components and polypeptides to supply chemical synthesis APIs for oncology, metabolism and nervous system therapeutic areas to proprietary and generic drug companies and signatory customers.

Aucun commentaire disponible.
Laissez votre note & commentaire